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CHAPTER – I 
INTRODUCTION 
Hypertension is an increasing important medical and public health 
issue. Hypertension markedly increases the risk for myocardial infarction, 
stroke, congestive heart failure, peripheral vascular disease and end stage 
renal disease.     
Worldwide prevalence estimates for hypertension may be as much 
as 1 billion individuals, and approximately 7.1 million deaths per year 
may be attributable to hypertension.(1)  The WHO reports that suboptimal 
blood pressure (>115 mm Hg Systolic BP) is responsible for 62% of 
cerebrovascular disease and 49% of ischemic heart disease, with little 
variation by sex.  In addition, suboptimal blood pressure is the number 
one attributable risk for death throughout the world.(1) 
Approximately 30% of adults are still unaware of their 
hypertension, more than 40% of individuals are not on treatment, and two 
thirds of hypertensive patients are not being controlled to BP levels less 
than 140/90 mm Hg.(1) 
Studies of uric acid levels and the development of hypertension 
have generally been consistent, continuous, and of similar magnitude.  
Hyperuricemia is also common among adults with prehypertension, 
especially when microalbuminuria is present(1). The observation that 
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hyperuricemia precedes the development of hypertension indicates that it 
is not simply a result of hypertension per se.(2) 
Uric acid is a purine metabolite that in most mammals is degraded 
by the hepatic enzyme uricase to allantoin.  However, mutations in the 
uricase gene occurred during primate development, with the consequence 
that humans have relatively higher levels of serum uric acid. 
An elevation in serum uric acid has been associated with an 
increased risk for the development of hypertension,(4,6) and 25% to 50% 
of hypertensive individuals are hyperuricemic6.  Hyperuricemia also 
confers increased risk for cardiovascular mortality, especially in 
women.(6,7) Despite the clinical and epidemiological evidence, many 
authorities do not consider an elevated uric acid to be a true 
cardiovascular risk factor, because patients with hyperuricemia often 
have other well-established risk factors for cardiovascular disease, such 
as hypertension, renal disease, obesity, dyslipidemia, and insulin 
resistance.   
Several studies have found that an elevated uric acid level is an 
independent risk factor for cardiovascular disease after controlling for the 
contribution of established risk factors by multivariate analyses.  The lack 
of a mechanism by which uric acid can cause cardiovascular disease, 
coupled with the inconclusive clinical and epidemiological data, has left 
the issue unresolved.   
 
 
 
 
AIM OF THE STUDY 
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CHAPTER – II 
AIM OF THE STUDY 
 
 Numerous studies have reported that hyperuricemia carries an 
increased relative risk for hypertension, independent of other risk factors. 
The aim of this study is  
1. To find the association of hyperuricemia in new-onset and recent 
onset Hypertensive patients.  
2. To find the association of hyperuricemia in hypertensive patients 
with regard to gender and risk factors like smoking, central obesity 
and BMI. 
3. To find the association of serum uric acid in hypertensive patients 
who have metabolic syndrome. 
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CHAPTER – III 
REVIEW OF LITERATURE 
 
Hypertension doubles the risk of cardiovascular diseases, including 
coronary heart disease (CHD), congestive heart failure (CHF), ischemic 
and hemorrhagic stroke, renal failure, and peripheral arterial disease. 
Hypertension is often associated with additional cardiovascular disease 
risk factors, and the risk of cardiovascular disease increases with the total 
burden of risk factors.(10) 
 
MECHANISMS OF HYPERTENSION 
1. INTRAVASCULAR VOLUME 
 The initial elevation of blood pressure in response to vascular 
volume expansion is related to an increase of cardiac output; however, 
over time, peripheral resistance increases and cardiac output reverts 
toward normal. 
 The mechanism for the “pressure-natriuresis” phenomenon may 
involve a subtle increase of glomerular filtration rate, decreased 
absorbing capacity of the renal tubules, and possibly hormonal factors 
such as atrial natriuretic factor.(10) 
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AUTONOMIC NERVOUS SYSTEM  
The autonomic nervous system maintains cardiovascular 
homeostasis via pressure, volume and chemoreceptor signals. Adrenergic 
reflexes modulate blood pressure over the short term, and adrenergic 
function, in concert with hormonal and volume-related factors, 
contributes to the long-term regulation of arterial pressure.(10) 
 
RENIN-ANGIOTENSIN-ALDOSTERONE-SYSTEM   
 The renin-angiotensin-aldosterone system contributes to the 
regulation of arterial pressure primarily via the vasoconstrictor properties 
of angiotensin II and the sodium-retaining properties of aldosterone.  
Angiotensin II is a potent pressor substance, the primary trophic factor for 
the secretion of aldosterone by the adrenal zona glomerulosa, and a potent 
mitogen stimulating vascular smooth-muscle cell and myocyte growth. 
Independent of its hemodynamic effects, Angiotensin II may play a role 
in the pathogenesis of atherosclerosis through a direct cellular action on 
the vessel wall.(10) 
 Aldosterone also has effects on nonepithelial targets. Independent 
of a potential effect on blood pressure, aldosterone may also play a role in 
cardiac hypertrophy and CHF. 
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RENIN ANGIOTENSIN ALDOSTERONE SYSTEM 
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 Pathologic patterns of left ventricular geometry have also been 
associated with elevations of plasma aldosterone concentration in patients 
with essential hypertension, as well as in patients with primary 
aldosteronism. 
 
PATHOLOGIC CONSEQUENCES OF HYPERTENSION 
1. HEART 
 Hypertensive heart disease is the result of structural and functional 
adaptations leading to left ventricular hypertrophy, diastolic dysfunction, 
CHF, abnormalities of blood flow due to atherosclerotic coronary artery 
disease and microvascular disease and cardiac arrhythmias. 
 Diastolic dysfunction is an early consequent of hypertension-
related heart disease and is exacerbated by left ventricular hypertrophy 
and ischemia. 
 
2. BRAIN 
         Hypertension is an important risk factor for brain infarction and 
hemorrhage. The incidence of stroke rises progressively with increasing 
blood pressure levels, particularly systolic blood pressure in individuals 
>65 years.(10) 
 Hypertension is also associated with impaired cognition in an aged 
population. Hypertensive encephalopathy is related to failure of 
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autoregulation of cerebral blood flow at the upper pressure limit, resulting 
in vasodilation and hyperperfusion. Untreated hypertensive 
encephalopathy may progress to stupor, coma, seizures, and death within 
hours. 
 
3. KIDNEY 
           Hypertension is a risk factor for renal injury and ESRD. The 
increased risk associated with high blood pressure is graded, continuous, 
and present throughout the entire distribution of blood pressure above 
optimal. Renal risk appears to be more closely related to systolic than to 
diastolic blood pressure. 
 The atherosclerotic, hypertension-related vascular lesions in the 
kidney primarily affect the preglomerular arterioles, resulting in ischemic 
changes in the glomeruli and postglomerular structures. Glomerular 
pathology progresses to glomerulosclerosis, and eventually the renal 
tubules may also become ischemic and gradually atrophic. 
 Clinically, macroalbuminuria (a random urine albumin/creatinine 
ratio > 300 mg/mg) or microalbuminuria (a random urine albumin / 
creatinine ratio 30-300 mg/mg) are early markers of renal injury.(10) 
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4. PERIPHERAL ARTERIES 
             Hypertensive patients with arterial disease of the lower 
extremities are at increased risk for future cardiovascular disease. The 
ankle-brachial index is a useful approach for evaluating Peripheral 
Arterial Disease and is defined as the ratio of noninvasively assessed 
ankle to brachial (arm) systolic blood pressure. An ankle-brachial index  
< 0.90 is considered diagnostic of Peripheral Arterial Disease. 
 
DEFINING HYPERTENSION 
From an epidemiologic perspective, there is no obvious level of 
blood pressure that defines hypertension. The multiple Risk Factor 
Intervention Trial (MRFIT), which included > 350,000 male participants, 
demonstrated a continuous and graded influence of both systolic and 
diastolic blood pressure on CHD mortality. 
Cardiovascular disease risk doubles for every 20-mmHg increase in 
systolic and 10-mmHg increase in diastolic pressure. Among older 
individuals, systolic blood pressure and pulse pressure are more powerful 
predictors of cardiovascular disease than diastolic blood pressure.(1,10) 
 
CRITERIA 
Recommended criteria for a diagnosis of hypertension are average 
awake blood pressure ³ 135/85 mmHg and asleep blood pressure  
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³ 120/75 mmHg. These levels approximate a clinic blood pressure of  
³ 140/90 mm Hg.(1,10) 
 
Classification of Blood Pressure for Adults 
 Based on the seventh report of JOINT NATIONAL 
COMMITTEE ON PREVENTION, DETECTION, EVALUATION 
AND TREATMENT OF HYPERTENSION (JNC 7). 
 
Table – 1 
JNC VII Classification 
Blood Pressure Classification Systolic, mmHg Diastolic, mmHg 
Normal < 120 and < 80 
Prehypertension 120-139 or 80-89 
Stage 1 hypertension 140-159 or 90-99 
Stage 2 hypertension ³ 160 or ³ 100 
Isolated systolic hypertension ³ 140 and £ 90 
 
 
ACCURATE BLOOD PRESSURE MEASUREMENT  
The accurate measurement of BP is the sine qua non for successful 
management. The   equipment, whether aneroid, mercury, or electronic, 
should be trained and regularly retrained in the standardized technique, 
and the patient must be properly prepared and positioned. The 
auscultatory method of BP measurement should be used. 
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Persons should be seated quietly for at least 5 minutes in a chair 
(rather than on an examination table), with feet on the floor, and arm 
supported at heart level. Caffeine, exercise and smoking should be 
avoided for at least 30 minutes prior to measurement. Measurement of BP 
in the standing position is indicated periodically, especially in those who 
report symptoms consistent with reduced BP on standing. An 
appropriately sized cuff (cuff bladder encircling at least 80% of the arm) 
should be used to ensure accuracy. At least two measurements should be 
made and the average recorded.                                                                                      
For manual determinations, palpated radial pulse obliteration 
pressure should be used to estimate SBP; the cuff should then be inflated 
20 to 30 mm Hg above this level for the auscultatory determinations; the 
cuff deflation rate for auscultatory readings should be 2 mm Hg per 
second. SBP is the point at which the first of two or more Korotkoff 
sounds is heard (onset of phase 1), and the disapperance of Korotkoff 
sound (onset of phase 5) is used to define DBP.   
In certain conditions like Aortic Regurtitation, the diastolic BP will 
be 0 mm Hg and the appearance of muffled sound is taken as diastolic 
BP.  Care should be taken while measuring BP in elderly patients as there 
will be auscultatory gap.  
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Recommendations for Follow-Up Based on Initial Blood Pressure 
Measurements for Adults without Acute End Organ Damage            
(JNC-7) 
 
Initial Blood Pressure, mm Hg* Follow-Up Recommended+ 
Normal Recheck in 2 years 
Prehypertension Recheck in 1 year 
Stage 1 
Hypertension 
Confirm within 2 months# 
Stage 2 
Hypertension 
Evaluate or refer to source of care 
within 1 month. For those with higher 
pressures (eg, > 180/110 mm Hg), 
evaluate and treat immediately or 
within 1 week depending on clinical 
situation and complications. 
* If systolic and diastolic categories are different, follow recommendations for shorter time follow-
up (e.g, 160/86 mm Hg should be evaluated or referred to source of care within 1 month). 
+ Modify the scheduling of follow-up according to reliable information about past BP 
measurements, other cardiovascular risk factors, or target organ disease. 
# Provide advice about lifestyle modifications.  
 
 
The key messages of JNC – VII are:(1) 
Ø In those older than age 50, systolic blood pressure of greater than 
140 mm Hg is a more important cardiovascular disease (CVD) risk 
factor than diastolic BP. 
Ø Beginning at 115/75 mm Hg, CVD risk doubles for each increment 
of 20/10 mm Hg. 
Ø Those who are normotensive at 55 years of age will have a 90% 
life time risk of developing hypertension. 
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Ø Prehypertensive individuals require health promoting lifestyle 
modifications to prevent the progressive rise in blood pressure and 
Cardio Vascular Disease. 
Ø For uncomplicated hypertension, thiazide diuretic should be used 
in drug treatment for most patients, either alone or combined with 
drugs from other classes. 
Ø Two or more antihypertensive drugs will be required to achieve 
goal BP (<140/90 mm Hg or <130 mm Hg) for patients with 
diabetes and chronic kidney disease. 
Ø For patients whose BP is more than 20 mm Hg above the systolic 
BP goal or more than 10 mm Hg above the diastolic BP goal, 
initiation of therapy using two agents, one of which usually will be 
a thiazide diuretic, should be considered. 
 
CLINICAL DISORDERS OF HYPERTENSION               
1. ESSENTIAL HYPERTENSION 
2. METABOLIC SYNDROME 
3. RENOVASCULAR HYPERTENSION 
4. PRIMARY ALDOSTERONISM 
5. CUSHING’S SYNDROME 
6. PHEOCHROMOCYTOMA 
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7. MISCELLANEOUS CAUSES OF HYPERTENSION 
 Obstructive sleep apnea, Coarctation of the aorta, acromegaly, 
hypercalcemia, both hypo and hyper thyroidism. 
8. MONOGENIC HYPERTENSION 
 
ESSENTIAL HYPERTENSION 
 Essential hypertension tends to be familial and is likely to be the 
non-sequence of an interaction between environmental and genetic 
factors. The prevalence of essential hypertension increases with age. In 
the majority of patients with established hypertension, peripheral 
resistance is increased and cardiac output is normal or decreased; 
however, in younger patients with mild or labile hypertension, cardiac 
output may be increased and peripheral resistance may be normal. 
High-renin patients may have a vasoconstrictor form of 
hypertension, whereas low-renin patients may have a volume-dependent 
hypertension.(10) 
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URIC ACID METABOLISM 
 
Uric acid is the final breakdown product of purine degradation in 
humans. Urates, the ionized forms of uric acid, predominate in plasma 
extracellular fluid and synovial fluid, with ~98% existing as monosodium 
urate at pH 7.4.(11) 
 The pH of urine greatly influences the solubility of uric acid. 
Although purine nucleotides are synthesized and degraded in all tissues, 
urate is produced only in tissues that contain xanthine oxidase, primarily 
the liver and small intestine. Urate production varies with the purine 
content of the diet and the rates of purine biosynthesis, degradation, and 
salvage. Normally, two-third to three-fourth of urate is excreted by the 
kidney, and most of the remainder is eliminated through the intestine. 
 
METABOLISM 
The kidneys clear urate from the plasma and maintain physiologic 
balance by utilizing specific organic anion transporters (OATs) including 
urate transporter 1 (URATI) and human uric acid transporter (hUAT). 
URAT1and other OATs carry urate into the tubular cells from the apical 
side of the lumen. Once inside the cell, urate must pass to the basolateral 
side of the lumen in a process controlled by the voltage-dependent carrier 
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hUAT. Until recently, component model has been used to describe the 
renal handling of urate / uric acid.  The methods are 
(1) Glomerular filtration,  
(2) Tubular reabsorption  
(3) Secretion, and  
(4) Postsecretory reabsorption. 
URAT1 is a novel transporter expressed at the apical brush border 
of the proximal nephron. Uric acid compounds directly inhibit URAT1 on 
the apical side of the tubular cell (so-called cis-inhibition).(11) 
 
The total-body urate pool is the net result between urate production 
and excretion 
 
 Urate production is influenced by dietary intake of purines and the 
rates of de novo biosynthesis of purines from nonpurine precursors, 
nucleic acid turnover, and salvaging phosphoribosyltransferase activities. 
The formed urate is normally excreted by urinary and intestinal routes. 
Hyperuricemia can be caused by increased production, decreased 
excretion, or a combination of mechanisms. When hyperuricemia exists, 
urate can precipitate and deposit in tissues as tophi. 
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URIC ACID TURNOVER AND METABOLISM 
 
De novo
biosynthesis Nucleic acids
Nucleotides
Diet Nucleosides
Bases
Urate
Urine Intestine
Tophi
Salvage pathways
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HYPERURICEMIA 
 Hyperuricemia is defined as a plasma (or serum) urate 
concentration > 6.0mg/dl in females and > 7.0mg/dl in males.(2,11,12) 
 
CAUSES OF HYPERURICEMIA 
 Hyperuricemia may be classified as primary or secondary 
depending on whether the cause is innate or is the result of an acquired 
disorder. 
 However, it is more useful to classify hyperuricemia in relation to 
the underlying pathophysiology, i.e., whether it results from increased 
production, decreased excretion, or a combination of the two. 
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Classification of hyperuricemia by pathophysiology 
Urate Overproduction 
Primary idiopathic Myeloproliferative 
diseases 
Rhabdomyolysis 
 HPRT deficiency Polycythemia vera Exercise 
PRPP synthetase  
Overactivity 
Psoriasis Alcohol 
Hemolytic processes Paget’s disease Obesity 
Lymphoproliferative 
diseases 
Glycogenosis III, V, 
and  
VII 
Purine-rich diet 
Decreased Uric Acid Excretion 
Primary idiopathic Starvation ketosis Drug ingestion 
Renal insufficiency Berylliosis Salicylates (> 2 g/d) 
Polycystic kidney  
disease 
Sarcoidosis Diuretics 
Diabetes insipidus Lead intoxication Alcohol 
Hypertension Hyperparathyroidism Levodopa 
Acidosis Hypothyroidism Ethambutol 
Lactic acidosis Toxemia of 
pregnancy 
Pyrazinamide 
Diabetic ketoacidosis Bartter’s syndrome Nicotinic acid 
Down syndrome Cyclosporine  
Combined Mechanism 
Alcohol Glucose-6-phosphatase 
deficiency  
Fructose-1-phosphate 
aldolase deficiency  Shock 
Note: HPRT, hypoxanthine phosphoribosyltransferase, PRPP, phosphoribosylpyrophosphate. 
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HISTORY OF URIC ACID AND HYPERTENSION 
 The concept that uric acid may be involved in hypertension is not a 
new one.  In fact, in the paper published in 1879 that originally described 
essential hypertension, Frederick Akbar Mohamed noted that many of his 
subjects came from gouty families.  He hypothesized that uric acid might 
be integral to the development of essential hypertension.(13) 
         Ten years later, this hypothesis reemerged when Haig(14) proposed 
low-purine diets as a means to prevent hypertension and vascular disease. 
In 1909, the French academician Henri Huchard noted that renal 
arteriolosclerosis (the histologic lesion of hypertension) was observed in 
three groups: Those with gout, those with lead poisoning, and those who 
have a diet enriched with fatty meat. All of these groups are associated 
with hyperuricemia.(15) 
 The association between elevated serum uric acid and hypertension 
was observed and reported repeatedly in the 1950s to 1980 but received 
relatively little sustained attention because of the lack of a mechanistic 
explanation.(16-18) 
Twenty-five to 40% of adult patients with hypertension have 
hyperuricemia (> 6.5 mg/dl), and this number increases dramatically 
when serum uric acid in the high-normal range is included.(19,20)  In pre-
eclampsia, the correlation between elevated serum uric acid and 
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hypertension is > 70%.(21) Despite these observations, the lack of a causal 
mechanism led to mild elevations of serum uric acid being largely 
ignored in medical practice.  
 The strength of the relationship between uric acid level and 
hypertension decreases with increasing patient age and duration of 
hypertension, suggesting that uric acid may be most important in younger 
subjects with early-onset hypertension. (18) 
Cross-sectional studies have consistently noted that more than a 
quarter of patients with untreated hypertension have elevated serum 
UA.(19,22)  Serum UA levels have also been associated cross-sectionally 
with BP(18,23,24) and longitudinally with hypertension incidence (4,5,27-29) 
and future increases in BP.(30) 
 
Mild hyperuricemia in the Rat, an animal model for essential 
hypertension 
 
 The study of mild hyperuricemia required an animal model before 
the lack of any mechanistic detail that had plagued the hypothesis over 
100 years could be addressed. 
          In the late 1990s, Johnson and Colleagues(31) developed a model 
using a pharmacologic inhibitor of urate oxidase, oxonic acid, that allows 
the study of sustained mild hyperuricemia.  When fed 2% oxonic acid in 
their standard diet, Sprague-Dawley rats have an increase of mean serum 
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uric acid concentrations from 0.5 to 1.4 g/dl to 1.7 to 3.0 mg/dl. During a 
7-wk treatment period, systolic BP increases an average of 22 mmHg.  
The increase in BP can be prevented entirely by the co-administration of 
the xanthine oxidase inhibitor allopurinol or by the uricosuric agent 
benziodarone, indicating linearly related to the rise in uric acid (r = 0.77). 
         Histologic evaluation of the renal tissue of the hyperuricemic, 
hypertensive rats reveals an expansion of the vascular smooth muscle and 
narrowing of the lumina of the afferent arterioles.  It is interesting that the 
development of arteriolosclerosis can be prevented using allopurinol to 
control uric acid levels; however, hydrochlorothiazide, which normalizes 
BP without lowering serum uric acid, does not prevent the development 
of arteriolosclerosis, indicating that uric acid, not hypertension, is the 
causative stimulus.(22,32) 
 These experimental results indicate that mild hyperuricemia 
induces renal inflammation, activation of the renin-angiotensin system, 
and downregulation of nitric oxide production, all of which are 
potentially important pathways that lead to uric acid-mediated 
hypertension. 
 In short, mild hyperuricemia leads to an irreversible salt-sensitive 
hypertension over time. 
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 Recent in vitro studies also have elucidated the possible 
mechanism of uric acid-mediated arteriolosclerosis.  Primary human 
vascular smooth muscle cells (HVSMC) are induced to proliferate by 
addition of uric acid to the growth medium in a dose-dependent 
manner.(33)  The human smooth muscle cells express the urate-transport 
channel URAT1 as evidenced by both Northern and Western analyses.  
Consistent with this observation, cultured HVSMC rapidly take up           
C-urate, and blockade of this uptake by probenecid attenuates the uric 
acid-mediated induction of proliferation in a dose-dependent manner.(34)  
Signaling studies have revealed further the possible mechanism by which 
urate uptake leads to HVSMC proliferation.(33,35,36) 
 
The effect of uric acid on vascular smooth muscle cells (VSMC) 
            Uric acid is taken up through the probenecid-sensitive urate-
transport channel URAT1.  This leads to mitogen-activated protein kinase 
activation and extracellular signal-regulated kinase 1 and 2 (Erk ½) 
Phosphorylation. In turn, transcription factors NF-b (nuclear transcription 
factor) and AP1 are activated leading to increased cyclo-oxygenase-2 
(COX-2) expression and activity.  The COX-2 product Thromboxane A2 
mediates increased expression and elaboration of platelet derived growth 
factor (PDGF) and monocyte chemoattractant protein-1 (MCP-1), which 
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induce VSMC proliferation and macrophage infiltration, 
respectively.(33,35,36) 
 
REMNANT KIDNEY MODEL 
                Various studies have investigated the effect of uric acid on 
multiple mechanisms of progressive renal injury.  In the remnant kidney 
model, Hyperuricemic remnant kidney rats (caused by addition of 2% 
oxonic acid to their diets) had higher BP, greater proteinuria, and higher 
serum creatinine.(37,38)  Addition of oxonic acid to cyclosporine treatment 
led to higher uric acid levels, more severe arteriolar hyalinosis, 
macrophage infiltration, and tubulointerstitial damage compared with rats 
that were treated with cyclosporine alone.(39)  Furthermore treatment of 
cyclosporine-exposed rats with allopurinol improves GFR(39), and in 
human liver transplant patients who were receiving cyclosporine, 
treatment with allopurinol resulted in improved renal function.(40) 
 
RECENT EPIDEMIOLOGY: A CHANGE IN PERSPECTIVE 
 Before 1990, only Khan et al.(27) had reported that an increased 
serum uric acid is an independent risk factor for hypertension; however, it 
had been noted that 25 to 40% of adults with hypertension have serum 
uric acid > 6.5 mg/dl and >60% have a serum uric acid > 5.5 mg/dl(19,20) 
and that there was a linear relationship between serum uric acid and 
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systolic BP.(41)  Three reports indicated that serum uric acid is an 
independent risk factor for hypertension were published in the 
1990s(25,26,29) and five more were published in the past 4 yrs(28,30,42,43,44), 
including two in the first month of 2005 (Table 2).  The recent evaluation 
of a subset of the Framingham Heart Study found that serum uric acid 
level was an independent predictor of hypertension and BP progression 
over as little as 4 yrs.(44) 
 
Uric acid and essential hypertension in children 
In adolescents, the association between elevated serum uric acid 
and the onset of essential hypertension is even more striking.  The 
Moscow Children’s Hypertension study found hyperuricemia                    
(> 8.0 mg/dl) in 9.5% of children with normal BP, 49% of children with 
borderline hypertension, and 73% of children with moderate and severe 
hypertension.(45) 
              The Hungarian Children’s Health Study followed all 17,624 
children who were born in Budapest in 1964 for 13yrs and found that 
significant risk factors for the development of hypertension were elevated 
heart rate, early sexual maturity, and hyperuricemia.(46) 
              Gruskin(47) compared adolescents (13 to 18yrs of age) who had 
essential hypertension with age-matched healthy control subjects and who 
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had normal BP.  The hypertensive children had both elevated serum uric 
acid (mean > 6.5 mg/dl) and higher peripheral renin activity.  
Feig and Johnson observed that the mean serum uric acid level 
(±SD) in control subjects and children with white coat hypertension were 
nearly identical but slightly higher in secondary hypertension (4.3 ± 1.4 
mg/dl, respectively; P = 0.80) but very high in children with primary 
hypertension (6.7 ± 1.3 mg/dl; P = 0.004) (38).  There was a tight, linear 
correlation between the serum uric acid levels and the systolic and 
diastolic BP in patients who were referred for evaluation of hypertension 
(r = 0.8 for systolic BP and r = 0.6 for diastolic BP).(24) 
Among patients who were referred for evaluation of hypertension, 
a serum uric acid > 5.5 mg/dl had an 89% positive predictive value for 
essential hypertension, whereas a serum uric acid level <5.0 had a 
negative predictive value for essential hypertension of 96%.(24) 
 The results from both animal and human studies strongly implicate 
uric acid as a factor in the onset of essential hypertension and as a 
potential contributor to the progression of renal injury.    
 
Evidence linking uric acid and hypertension 
1. An elevated uric acid level consistently predicts the development of 
hypertension.(25-29) 
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2. An elevated uric acid level is observed in 25-60% of patients with 
untreated essential hypertension and in nearly 90% of adolescents with 
essential hypertension of recent onset.(24) 
3. Raising the uric acid level in rodents results in hypertension with the 
clinical, hemodynamic, and histologic characteristics of 
hypertension.(31) 
4. Reducing the uric acid level with xanthine oxidase inhibitors lowers 
blood pressure in adolescents with hypertension of recent onset.(48) 
 
MECHANISM OF HYPERTENSION IN HYPERURICEMIA - RAT 
MODEL 
 
Most mammals have a low serum uric acid level because of the 
presence of uricase, a hepatic enzyme that degrades uric acid to allantoin.  
However in humans the uricase gene is mutated resulting in uric acid 
levels that are both higher and less regulatable than in other mammals.  
Interestingly when mild hyperuricemia was induced in rats by the 
administration of a uricase inhibitor, they became hypertensive.   
Hypertension in this model was mediated by 2 mechanisms. 
1. Uric acid induced renal vasoconstriction mediated by endothelial 
dysfunction with reduced NO levels and by activation of the renin-
angiotensin system.  This hypertension type is salt-resistant in that it 
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occurs even in the presence of a low-salt diet, and it responds to lowering 
of uric acid. 
2. Later, however, the hyperuricemia causes progressive renal 
microvascular disease (a lesion resembling arteriolosclerosis), and once 
sufficient narrowing of the arteriolar lumen occurs, a component of the 
hypertension becomes salt-driven, renal-dependent, and independent of 
uric acid levels. 
The identification of a biological mechanism by which uric acid 
could cause hypertension in humans has led to a renewed interest in the 
role of uric acid in hypertension. Indeed, there are now 10 studies that 
have examined whether an elevated uric acid level predicts the 
development of hypertension, and all found uric acid predictive. 
The Bogalusa Heart study, found that uric acid levels in childhood 
predict the development of diastolic hypertension 10 years later.  The 
second study, from the Framingham group(44), also found uric acid to 
predict the development of hypertension.  This latter study is all the more 
remarkable as it was performed in an older population (mean age 50) in 
which they first eliminated 25% of their subjects because they already 
had hypertension or gout, thereby removing a large proportion of their 
target population. 
 
  29 
PROPOSED MECHANISM FOR URIC ACID MEDIATED 
HYPERTENSION IN HUMANS(2) 
 
Excessive intake of fructose or purine-rich meats or exposure to 
low doses of lead may result in chronic hyperuricemia.  Mothers with 
high uric acid levels that are the result of diet or conditions such as 
preexisting hypertension, obesity, or preeclampsia may transfer uric acid 
into the fetal circulation through the placenta, which may ultimately 
contribute to intrauterine growth retardation (IUGR) and a reduction in 
nephron number.  Among babies born with a low nephron number, 
hyperuricemia may develop in childhood because of genetic or 
environmental factors. Chronic hyperuricemia would stimulate the renin-
angiotensin system and inhibit release of endothelial nitric oxide 
contributing to renal vasoconstriction and possibly increasing blood 
pressure.  Persistent renal vasoconstriction may contribute to 
arteriolosclerosis and the development of salt-sensitive hypertension, 
even if the hyperuricemia is corrected.  
  30 
 
 
PROPOSED MECHANISM FOR URIC ACID MEDIATED  
HYPERTENSION IN HUMANS (2) 
 
 
Maternal
  Factor
Placental
  Factor
Uric acid?
IUGR
Low nephron number      Genetic or
environmental factors
      Purine-rich or
fructose-heavy diet or
    exposure to lead
Increased uric acid
Increased renin and decreased
Nitric Oxide
Interstitial inflammation
Microvascular inflammation
Afferent arteriopathy
Interstitial fibrosis
Decreased nitric oxide and
increased ROS
Vascular inflammation
Proliferation of vascular smooth
muscle cells with inhibition of
endothelial cell growth
Early stage
Uric-acid-induced vasoreactive hypertension
Late stage
Salt-sensitive kidney-dependent hypertension  
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Table - 2 
Epidemiological studies suggested that serum uric acid 
predicts hypertension 
Author Year published Study size 
Duration of 
Follow-up (yr) 
Increased 
Risk 
Kahn et al.(27) 1972 10,000 
men 
5 2-fold 
Selby et al.(26) 1990 2062 adults  6 3-fold 
Hunt et al.(29) 1991 1482 adults  7 2-fold 
Jossa et al.(25) 1994 619 men 12 1.2-fold 
Taniguchi et al.(42) 2001 6356 men 10 2-fold 
Masuo et al.(30) 2003 433 men 5 +27 mmHg 
in systolic 
BP per each 
1-mg/dl 
change in 
uric acid 
Nakanishi et al.(28) 2003 2310 men 6 1.6-fold 
Nagahama et al.(49) 2004 4489 adults  23 1.5-fold in 
men 
Alper et al.(43) 2005 577 
children  
11 Predicts 
diastolic 
hypertension 
Sundstrom et al.(44) 2005 3119 adults  4 1.5-fold 
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CHAPTER – IV 
MATERIALS AND METHODS 
 
 
Study Setting 
 Annal Gandhi Memorial Government Hospital and K.A.P. 
Viswanatham Government Medical College, Trichy.  The collaborative 
department was Department of Biochemistry, K.A.P. Viswanatham 
Government Medical College.  
 
Study design 
 Analytical study. 
 
Period of study 
 October 2008 to September 2009. 
 
Ethical Committee Approval 
 The study was approved by the Ethical Committee, Trichy. 
 
Patient Population 
Cases 
 One hundred adults aged between 20-50 years were selected for the 
study and referred consecutively to the Hypertension OPD of Annal 
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Gandhi Memorial, Government Hospital, Trichy. They were studied for 
Serum Uric acid levels. 
 
Controls 
 Normotensive controls (n = 100) were selected for the study and 
evaluated for clinical and laboratory data. 
 Both males and females were included for the study. All subjects 
and controls had normal renal function (Renal biochemistry, USG 
Abdomen). 
 
Inclusion Criteria 
1. Hypertensive patients, whom are of new-onset and recent onset       
(<1 yr) without any target end organ damage. 
2. Age group between 20 to 50 years. 
3. Both sexes were included. 
4. Stage 1 and stage 2 Hypertension according to JNC-VII. 
 
Exclusion Criteria 
1. Hypertensive patients with Target End Organ damage  
1. Hypertensive Heart disease as evidenced by Left 
Ventricular hypertrophy - ECG-voltage criteria. 
2. Hypertensive Nephropathy 
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3. Hypertensive Retinopathy   
2. Diabetes Mellitus – Type 1 and Type 2 or metabolic syndrome 
3. Patients with Chronic kidney disease. 
4. Hypertensive Patients with known Cerebro vascular disease. 
5. Hypertensive Patients with coronary Artery disease - Myocardial 
Ischemia or Infarction. 
6. Patients with long term drug intake like steroids, Anti-Tuberculous 
Treatment (ATT), diuretics, antimetabolite or chemotherapy drugs. 
7. Patients who were regularly consuming alcohol – Alcohol dependence 
subjects - Evidenced by History, liver function tests and USG 
Abdomen. 
8. Patients of Lympho or Myelo proliferative disorders. 
9. Patients who had chronic liver disease and metabolic disorders. 
10. Endocrine disorder – Hypothyroid patients. 
11. Psoriasis patients. 
12. Patients in whom BMI >30. 
13. Hypertensive crisis / Malignant Hypertension  
 
Consent 
 The study groups identified by the above criteria (inclusion and 
exclusion) were first informed about the nature of the study.  Participants 
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willing for the study were selected after getting an informed and written 
consent from them. 
 Thus, a total of 100 patients were taken up for study who satisfied 
the inclusive and exclusion criteria. Similarly, 100 age and sex matched 
subjects were kept as control. 
 There was no conflict of interest and financial support was Nil. 
Urinary excretion and urate clearance were not done, only serum 
uric acid levels were analysed. 
 
Patient profile 
Selected socio-demographic, clinical and laboratory data were 
collected from the cases and controls and recorded in proforma. 
 
1. Socio-demographic profile 
Ø Age 
Ø Sex 
Ø Occupation. 
Ø Cardiovascular risk factors – smoking, family history 
 
2. Clinical profile 
§ Body weight 
§ Height 
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§ Body mass index 
§ Waist circumference 
§ Pulse 
§ Systolic and diastolic blood pressure – Average of 2 BP 
measurements 
§ Clinical examination 
 
Evaluation of subject and controls 
 Laboratory analyses, performed in Biochemical laboratory at the 
AGM Government Hospital, Trichy included blood tests for the 
evaluation of renal parameters, fasting blood sugar, serum electrolytes, 
uric acid, lipid profile, thyroid function tests. 
§ Complete urinalyses were performed by the pathological faculty. 
§ ECG was taken for all the subjects and controls to rule out 
coronary artery disease and left ventricular hypertrophy. 
§ Fundus examination was done for all subjects. 
Definitions used in the present study 
1. Hypertension 
 Hypertension is defined as systolic blood pressure of ³ 140mmHg 
or diastolic blood pressure ³ 90 mmHg. 
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Blood pressure classification: By JNC VII 
Normal Systolic, mm Hg Diastolic mm Hg 
Pre hypertension 120-139 or 80-89 
Stage 1 140-159 or 90 – 99 
Stage 2 ³ 160 or ³ 100 
Isolated systolic hypertension ³ 140 and < 90 
 
2. Hyperuricemia 
 Hyperuricemia is defined as serum uric acid level more than > 7.0 
mg/dl in Indian men and > 6.0mg/dl in Indian women. (2,11,12) 
3. Body Mass Index 
 It is calculated by using the following formula 
  = 2metresin Height 
kgweight  
4. Waist circumference 
 The waist is measured by taking a circumference that gives the 
narrowest measurement between the rib cage and the iliac crest. It is an 
important component of the diagnostic criteria for the metabolic 
syndrome. It is a simple, convenient and reliable marker for intra 
abdominal fat and total body fat. 
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Central obesity 
According to NCFP: ATP III (National Cholesterol) Education 
program Adult Treatment Panel III) 
Waist circumference > 102 cm in males > 88 cm in females.  
Body Mass Index > 30, is usually classified as obesity. Body mass 
index between 25 to 30 should be viewed as medically significant, 
especially in the presence of other risk factors like hypertension, diabetes. 
Large scale epidemiological studies suggest that cardiovascular morbidity 
begins to rise when body mass index > 25, suggesting that the cut off for 
obesity should be lowered. 
 
5. Metabolic syndrome 
 NCEP: ATP III 2001. 
 
Three or more of the following: 
1. Central obesity 
Waist circumference >102 cm (m) > 88cm (F) 
2. Hypertriglyceridemia 
Triglycerides ³ 150mg / dl or specific medication. 
3. Low HDL cholesterol: < 40 mg / dl (M) and < 50 mg / dl (F) or 
specific medication. 
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4. Hypertension: Blood pressure ³ 130 mm Hg systolic BP or ³ 85 mm 
Hg diastolic BP or specific medication. 
5. Fasting plasma glucose ³100 mg/dl or specific medication or 
previously diagnosed type 2 diabetes. 
 
Laboratory Data 
§ Blood urea estimation was done manually by using urease GLDH 
(Glutamate and Lactate De-Hydrogenase) method. 
§ Serum creatinine estimation was done by using modified Jaffes 
method and calibrated by fully automated random access 
Biochemistry analyzer XL 300. 
§ Serum uric acid was done by using uricase method and calibrated 
by fully automated random access Biochemistry analyzer XL 300. 
§ Blood Glucose was estimated by using GOD / POD (Glucose 
oxidase and peroxidase) method and estimated by ERBA auto 
analyzer. 
 
Principle of Uric acid estimation 
 Uric acid is converted by uricase to allantoin and hydrogen 
peroxide in the presence of peroxidase, oxidizing the chromogen to a red 
coloured compound which is read at 500 nm. 
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1) Uric acid + 2H2O + O2 ¾¾ ®¾uricase  Allantoin + CO2 + H2O2. 
2) 2H2O2 + 4 Aminopyrine ¾¾¾¾¾ ®¾ daseDHBSPeroxi  Red Quinolone + H2O 
+ HCl 
(DHBS – 3,5 – Dichloro – 2-Hyroxy Benzene Sulphonic acid) 
 
Statistical Analysis 
 Data was entered in Microsoft excel spread sheet and analyzed 
statistically using standard statistical software.  Significance testing of the 
difference between means was done by unpaired 2 – tailed student ‘t’ 
test, and correlations were assessed by Pearson coefficient.  Significance 
was considered, if the ‘p’ value was below 0.05. 
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CHAPTER – V 
OBSERVATIONS AND RESULTS 
 
 The total number of subjects included in this study was 200.  Of 
these 100 were study cases (Hypertensive without target end organ 
damage) and another 100 were controls (Non – Hypertensive). 
 Both the cases and controls selected were adjusted for age 
distribution, Sex, BMI, selected cardio vascular risk factors like smoking, 
family history. 
 At the end of the study, 30 subjects in study group were found to 
have metabolic syndrome according to NCEP : ATP III criteria.  
Similarly 10 of the 100 controls satisfied the criteria for metabolic 
syndrome. 
 Both the cases and controls whom had met the criteria for 
metabolic syndrome were excluded from the study. 
 Many studies previously published had indicated that 
hyperuricemia is also associated with metabolic syndrome, as other 
conditions like coronary artery disease, stroke, pre eclampsia, malignant 
hypertension and chronic kidney disease. 
 Thus, subjects selected for the study after excluding metabolic 
syndrome were:  Cases – 70;   Controls – 90 
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Table – 1 
Selected Subjects for the study 
Metabolic Syndrome Cases Controls 
+ 30 10 
- 70 90 
Total 100 100 
 
Subjects finally selected 
Cases – 70  Controls – 90 
 
 
Distribution of Socio-demographic and clinical profile in cases and 
controls 
 
Table – 2 
S. No.  Cases Controls 
1. Total 70 90 
2. Gender M = 43; F = 27 M = 52; F = 38 
3. Mean Age 37.34 37.21 
4. BMI 20.96 to 30.00 20.59 to 29.38 
5. Mean BMI 25.07 24.99 
6. Waist Circumference 82 – 106 cms. 80 – 106 cms. 
7. Blood Pressure    
 Mean SBP (mm Hg) 155.85 113.00 
 Mean DBP (mm Hg) 101.92 74.12 
8. Uric Acid (mg / dl) 3.0 – 8.2 3.0 – 7.2 
9. Mean Uric Acid 5.71 3.87 
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Analysis of Cases and Controls in Relation to Age 
 The age of the subjects in both groups ranges from 20 – 50 yrs.  
The mean and standard deviation for age of the cases and controls are 
37.34 ± 2.7 and 37.21 ± 2.6 respectively, there is no significant difference 
among the cases and controls with reference to the age (p = 0.35, not 
significant). 
Table - 3 
Cases and Controls in relation to age 
Cases* Controls 
Age Group 
No. % No. % 
20-30 15 21.43 23 25.56 
30-40 23 32.86 32 35.56 
40-50 32 45.71 35 38.89 
Mean 37.3429 37.2111 
S.D. 2.67243 2.59927 
* P = 0.353 (not significant) 
 
  
 
 Both the study and control groups are comparable with regard to 
age distribution as evidenced by the following bar diagram. 
 
 
Fig. 1 
Cases and Controls in relation to age 
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 Analysis of Cases and Controls with regard to Sex Distribution 
 In 70 cases the subjects involved in this study are 43 males and 27 
females.  In 90 controls, there are 52 males and 38 females. 
 
Table - 4 
Cases and Controls in relation to gender 
Cases* Controls 
Sex 
No. % No. % 
Male 43 61.4 52 57.8 
Female 27 38.6 38 42.2 
* P = 0.240 (Not significant) 
 
 
The Sex distribution of the study group and control group does not 
differ. 
 
Fig. 2 
Cases and Controls in relation to gender 
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 Analysis of cases and controls in relation to BMI 
 The study subjects whose BMI > 30 are excluded from the study as 
BMI >30 has a strong association with hyperuricemia. 
 The mean and standard deviation of BMI for the cases and controls 
are 25.06 ± 2.5 and 24.99 ± 2.88 respectively.  The details are shown in 
Table 5 given below. 
 There is no significant difference among cases and controls with 
regard to BMI. 
Table - 5 
Cases and Controls with respect to BMI 
Cases* Controls 
BMI 
No. % No. % 
< 25 30 42.86 41 45 
25-30 40 57.14 49 54 
Mean 25.07 24.99 
S.D. 2.56 2.88 
* P = 0.205 (Not Significant) 
 
 
The following bar diagram shows both the study and control 
groups are comparable with regard to BMI. 
Fig. 3 
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Distribution of cases and controls in relation to selected 
cardiovascular risk factors 
  
Table - 6 
Cases and Controls in relation to Selected Cardiovascular 
Risk Factor - Smoking (Males) 
Cases* Controls 
Smoking 
No. % No. % 
Yes 26 60.47 30 57.69 
No 17 39.53 22 42.31 
Total 43 100 52 100 
 
P = 0.655 (Not Significant) 
 
Table – 7 
Selected Cardiovascular Risk Factor – Family History 
Cases* Controls Family 
History No. % No. % 
Yes 40 57.1 49 54.4 
No 30 42.9 41 46.6 
 
P = 0.404 (Not Significant) 
 
Both the groups are comparable with regard to selected 
cardiovascular risk factors. 
 
 
Fig. 4 
Cases and Controls in relation to Smoking (Males) 
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Fig. 5 
Cases and controls in relation to Family History 
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Distribution of blood pressure in cases and controls 
 The mean and standard deviation of systolic blood pressure in 
cases and controls are 155 ± 12.7 and 113.00 ± 7.41 respectively. 
 Similarly, the mean and standard deviation of diastolic blood 
pressure in cases and controls are 101 ± 17.35 and 74 ± 8.39 respectively. 
 
Table - 8 
Cases and Controls in relation to Blood Pressure 
Cases* Controls Blood 
Pressure Mean S.D. Mean S.D. 
Systolic  155 12.73 113 7.41 
Diastolic 101 17.35 74 8.39 
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Analysis of Serum Uric Acid in study and control groups 
 Serum uric acid in the study population and control varied from 3.0 
to 8.2 mg/dl and 3.0 to 7.2 mg/dl respectively.  The mean and standard 
deviation of uric acid among cases is 5.71 ± 1.06, while in control it is 
3.87 ± 0.84 respectively. 
 The details are given in the table 9 and table 10 below. 
Table – 9 
Serum Uric Acid in Cases and Controls 
Cases Controls 
Mean S.D. Mean S.D. Serum Uric Acid 
5.71 1.07 3.87 0.84 
P = 0.021 (Significant) 
 
Table - 10 
Hyper Uricemia in Cases and Controls  
Cases Controls Hyper 
Uricemia No. % Mean SD No. % Mean SD 
Present 21 30.0 6.98 0.69 04 04.4 7.12 0.39 
Absent 49 70.0 5.18 0.70 86 95.6 3.72 0.50 
P = 0.021 (Significant) 
 
 
Fig. 6 
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Analysis of Gender Distribution of cases with regard to Serum Uric 
Acid 
 
 The mean of serum uric acid in males is 6.12 ± 0.5 and 5.5 ± 0.7 in 
females.  The details are shown in the following Table 11. 
Table – 11 
Serum Uric Acid values in relation to gender among cases 
Cases 
Sex 
No. Mean SD P 
Male  43 6.12 0.49 
Female 27 5.50 0.70 
0.0309 
Significant 
 
From this study mean uric acid levels is higher in males than 
females and the statistical difference is significant. 
 
 
Fig. 8 
Serum Uric Acid values in relation to gender among cases 
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 Serum Uric Acid in relation to BMI in cases 
 The mean and standard deviation of serum uric acid in study 
subjects whose BMI < 25 is 5.50 ± 0.99 and in whose BMI > 25 is              
5.86 ± 1.1.  The statistical difference found is not significant between the 
two groups as the p value = 0.362 (Not significant). 
 The details are shown in Table 12 given below. 
Table – 12 
Uric acid in relation to BMI in cases 
BMI Number Mean of Uric Acid S.D. 
< 25 30 5.50 0.99 
> 25 40 5.86 1.10 
P = 0.362 (Not Significant) 
 
 The study shows the uric acid level between two groups (BMI < 25 
and > 25) does not differ. But Nakanishi et al. showed that hyperuricemia 
is more correlated with low BMI subjects than high BMI subjects in 
hypertension.  
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Analysis of uric acid in relation to waist circumference abnormality 
Table – 13 
Waist abnormality and hyper uricemia in cases 
Waist Abnormality 
(Males > 102 cm; 
Females > 88 cm) 
Number Mean of Uric Acid S.D. 
+ 9 5.8889 0.75572 
- 61 5.6836 1.10773 
P = 0.578 (Not Significant) 
 
 Waist circumference is a reliable marker for central obesity.  Waist 
abnormality is said to be present in males if it is more than 102 cm, and in 
females more than 88 cm. 
 The mean and standard deviation of uric acid in cases with waist 
abnormality is 5.88 ± 0.75 and in subjects without waist abnormality is 
5.68 ± 1.1.  There is no significant difference between the two groups. 
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Analysis of Uric acid in relation to smoking (males) 
The mean & standard deviation of uric acid in cases with history of 
smoking is 5.3 ± 1.14.  Similarly the mean and standard deviation in 
cases without history of smoking is 6.27 ± 1.17.  There is no significant 
difference between the two groups with regard to uric acid as the P value 
is 0.56. 
Table – 14 
Smoking and Uric acid in cases  
Smoking Number Mean of Uric Acid S.D. 
+ 26 5.38 1.14 
- 17 6.27 1.17 
P = 0.56 (Not Significant) 
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Analysis of Uric acid and metabolic syndrome 
 Out of 100 cases 30 subjects were found to have metabolic 
syndrome.  Similarly, out of 100 controls 10 subjects were found to have 
the syndrome.  The mean & standard deviation of uric acid in cases with 
metabolic syndrome is 6.13 ± 0.91 and in controls it is 3.68 ± 0.94. 
 The statistical test shows a significant difference between the two 
groups with regard to metabolic syndrome.  (P value = 0.039) as also 
evidenced by other studies.  The details are given in the following table 
no.15. 
Table – 15 
Uric acid and metabolic syndrome 
Cases Controls Metabolic 
syndrome No. % Mean SD No. % Mean SD 
Present 08 27 01 10 
Absent 22 73 
6.13 0.91 
09 90 
3.68 0.94 
P = 0.039 (Significant) 
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CHAPTER - VI 
DISCUSSION 
 
 In this study, the relation of serum uric acid to BP in new and 
recent onset hypertensive adults without any target end organ damage 
was examined.  The study was based on strong epidemiologic data that 
have linked serum uric acid to hypertension in humans(18,19,22-29) and 
experimental animal data, which suggest that hyperuricemia contributes 
to hypertension.(31,32) 
The experimental studies further demonstrated that hyperuricemia 
caused preglomerular vascular disease via a BP-independent pathway (31), 
and once vascular changes were established, the hypertension was driven 
by the kidney, and lowering uric acid levels was no longer protective.(31)  
It is therefore hypothesized that if serum uric acid were important in the 
genesis of primary hypertension, then the relation would be greatest in the 
new and recent onset hypertensive subjects. 
 To test this hypothesis, 70 adults of which 43 males and 27 females 
referred for hypertension were evaluated.  Both the cases and controls 
selected were matched for age, sex and BMI.  The subjects in our sample 
included both young and old (20 to 50 years), but most of the studies 
included only younger subjects.  Because Nakanishi et al.(28) found a 
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strong association among those with lower BMI, a possible relationship 
between UA and BMI (< 25 and > 25 kg/m2) was also examined. 
The mean age of the study population was 37.3 and 37.2 in both 
cases and controls respectively. 
Blood pressure in both controls and cases were measured according 
to JNC VII classification and the mean blood pressure in cases was 155 / 
101 and in controls it was 113 / 74 respectively. 
 Uric acid was normally distributed among both subjects and was 
examined as a continuous variable.  The mean plasma uric acid in cases 
was 5.7 mg/dl ± 1.0 (range 3.0 to 8.2) and the mean plasma uric acid in 
controls was 3.8 mg/dl ± 0.8 (range 3.0 to 7.2).  The association between 
uric acid and hypertension was analyzed using student ‘t’ test and 
statistical difference was assessed by Pearson coefficient. 
 The study showed a significant difference between the 
hypertensive subjects and the normotensive controls (p value = 0.021). 
If uric acid was simply a marker, then a similar degree of 
hyperuricemia in the control subjects would be expected, and this was not 
observed. 
 Though mean uric acid was higher is subjects with BMI ³ 25 
(5.86) than those subjects with BMI < 25 (5.50) the relationship between 
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uric acid and BMI did not show a statistical difference in this study, but 
Nakanishi et al. found a stronger association among those with lower 
BMI. 
 Males were found to be more hyperuricemic than females in the 
study in which the difference is significant (p = 0.03). 
 Many studies have showed that hyperuricemia is closely associated 
with waist abnormality. The study revealed that there was not a 
significant difference between waist abnormality and uric acid in cases  
(p = 0.57). 
 The study also examined a possible relationship between smoking 
and hyperuricemia in hypertensive individuals. It was to observe that 
whether smoking influences hyperuricemia in hypertension.  
 The study showed that there is no significant difference between 
smoking (present or absent) and hyperuricemia (P = 0.56). 
 The study also examined a relation between metabolic syndrome 
and uric acid. Uric acid is associated with metabolic syndrome as 
indicated by various studies. It was also observed that a significant 
difference was obtained by the test between the two groups (P = 0.039). It 
is also to be noted that the sample size in both groups were small. 
There is a future perspective that hypertension can be treated by 
lowering uric acid levels particularly in new and recent onset 
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hypertension. Once microvascular lesion develops, lowering uric acid 
levels will not be useful, as the late stage hypertension is uric acid 
independent and salt sensitive.  
One study showed (48) lowering uric acid levels in adolescent 
hypertension resulted in BP reduction. The results represent a new 
potential therapeutic approach, although not a fully developed therapeutic 
strategy due to potential adverse effects. These preliminary findings 
require confirmation in larger clinical trials.  
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CHAPTER - VII 
CONCLUSION 
 
Ø Serum uric acid is strongly associated with BP in new and recent 
onset primary hypertension.   
Ø An elevated or high–normal serum uric acid value>5.5mg/dl(19,20,24) 
(mean uric acid-5.7 in this study) in an adult being evaluated for 
hypertension strongly supports the presence of primary 
hypertension. The remarkable association of uric acid with BP in 
adults is consistent with recent animal model data and the 
hypothesis that uric acid might have a pathogenic role in the 
development of hypertension. 
Ø Males have a higher degree of hyperuricemia than females in 
hypertensive patients. 
Ø Though mean uric acid is higher in study subjects whose BMI > 25 
than those subjects with BMI < 25, the association is not 
significant. 
Ø There is no stronger association of hyperuricemia in hypertension 
patients with regard to waist abnormality. 
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Ø There is no significant difference among hypertensive males with 
regard to uric acid and smoking. Smoking does not show an 
influence on hyperuricemia in cases. 
Ø Hyperuricemia is associated with metabolic syndrome, as 
evidenced by other studies. 
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PROFORMA 
 CHAPTER – IX 
ANNEXURE 
A STUDY ON THE ASSOCIATION OF SERUM URIC ACID IN 
NEW & RECENT ONSET PRIMARY HYPERTENSION 
 
PROFORMA 
 
NAME:   AGE:  SEX:  O.P.NO: 
OCCUPATION:  ADDRESS: 
HISTORY: - Headache   - Breathlessness  
  - Giddiness  - Palpitation 
  - Chest pain  - Edema legs 
 
PAST HISTORY: 
1) HT-YES/NO   DURATION:   Rx DETAILS: 
2) DM-YES/NO   DURATION:   Rx DETAILS: 
3) CKD-YES/NO   DURATION:   Rx DETAILS: 
4) CCF-YES/NO   DURATION:   Rx DETAILS: 
DRUG HISTORY: YES/NO  CVA - YES/NO  GOUT-YES/NO 
CAD-YES/NO   MALIGNANCY: YES/NO 
SKIN DISORDERS: YES/NO THYROID DISORDER-YES/NO 
 
PERSONAL HISTORY:  
DIET: SALT RESTRICTED: YES/NO 
SMOKING: YES/NO  ALCOHOL: YES/NO TOBACCO: YES/NO  
 FAMILY HISTORY: 
GENERAL EXAMINATION: 
HT:  WT:  BMI:  WAIST: 
ANAEMIA 
CYANOSIS 
CLUBBING 
PEDAL EDEMA 
ICTERUS 
GENERALISED LYMPHADENOPATHY 
THYROID 
VITALS: PR 
 BP -   LEFT ARM  RIGHT ARM 
   1. 
   2. 
   MEAN:  
Higher of the mean: 
SYSTEMIC EXAMINATION: 
CVS: 
RS: 
ABD: 
CNS: 
FUNDUS EXAMINATION: 
 
 
 INVESTIGATIONS: 
1. COMPLETE HAEMOGRAM - 
 
2. URINE-ALBUMIN  - 
 SUGAR   - 
 DEPOSITS   - 
3. FASTING BLOOD SUGAR - 
4. BLOOD UREA  - 
5. SERUM CREATININE - 
6. SERUM URIC ACID  - 
7. LIPID PROFILE  - TOTAL CHOLESTROL 
TRIGLYCERIDES 
      HDL 
      LDL 
      VLDL 
8. LIVER FUNCTION  - SERUM BILIRUBIN  
TRANSAMINASES, 
ALKALINE PHOSPHATASE,  
SERUM ALBUMIN AND 
GLOBULIN 
 
9. THYROID FUNCTION TESTS- T3, T4, TSH 
10. ECG    - 
 
 
 
 
MASTER CHART 
 
 
 
 
CASES 
 
S.No Name Age Sex Op.No Ht Wt BMI Waist BP Smoking Family History Urea Sugar Creatinine Cholestrol TGL HDL 
Metabolic 
syndrome UA xx 
1 Rajendran 45 1 2808 168 62 21.97 100 170/100 1 1 24 9.8 0.6 181 178 42 2 5.4 2 
2 Pushpa 35 2 63000 155 69 28.72 87 160/100 - 1 29 109 0.8 180 165 52 2 7.5 2 
3 Rajendran 48 1 82458 169 72 25.21 99 150/80 2 1 33 90 0.8 203 168 45 2 4.7 2 
4 Ravi 41 1 517 165 60 22.04 98 160/90 1 1 30 98 0.7 210 240 38 1 5.7 2 
5 Vetrivel 30 1 2807 170 65 22.49 94 160/90 1 1 25 95 0.7 180 40 42 2 6 2 
6 Mahabunisha 36 2 4738 152 62 26.84 86 140/96 - 1 26 101 4.8 158 195 38 1 4.1 2 
7 B.K. Balu 33 1 5959 159 70 27.69 100 180/106 2 1 26 98 0.5 48 138 41 2 8.2 2 
8 Ahamed 43 1 1939 172 68 22.99 99 150/100 1 1 24 110 0.7 161 210 47 1 4.5 2 
9 Maheswari 45 2 2875 159 60 23.73 90 150/92 - 2 25 96 0.6 183 191 45 2 5.2 2 
10 Kalaiselvan 38 1 377 172 64 21.63 106 150/90 1 1 22 85 0.8 162 140 37 1 4 2 
11 Murugan 24 1 4192 169 75 26.26 96 160/90 2 1 22 98 0.7 98 210 42 2 7.7 2 
12 Palani 45 1 425 172 75 25.35 96 150/90 2 2 22 97 0.6 217 16 38 2 5.7 2 
13 Ramesh 38 1 508 175 70 22.86 95 140/90 2 1 26 112 0.7 145 204 42 2 4.5 2 
14 Maruthamuthu 37 1 615 170 69 23.88 104 150/90 2 1 24 70 96 221 380 35 1 4.2 2 
15 Padmavathy 40 2 619 158 70 28.04 90 160/110 - 1 24 85 0.6 216 110 52 2 5.8 2 
16 Kannan 36 1 2709 165 70 25.71 96 150/90 1 1 25 91 0.6 110 275 36 2 5.2 2 
17 Jesudhass 41 1 1224 170 69 23.88 99 160/90 2 1 25 81 0.8 197 183 38 2 4.6 2 
18 Thangaraj 40 1 4538 175 64 21.1 100 160/100 2 1 24 100 0.7 191 220 40 2 6 2 
19 Ayeehaseevi 46 1 2086 159 67 26.5 88 150/100 - 2 28 95 0.7 190 190 51 2 6.2 2 
20 Thangaponnu 30 2 2539 156 69 28.35 86 140/90 - 2 25 96 0.6 180 143 55 2 5.5 2 
21 Jawahar 23 1 2619 174 79 26.09 92 150/90 - 1 25 96 0.6 183 191 46 2 5.2 2 
22 Duraisamy 42 1 624 169 63 22.06 98 160/90 1 1 26 93 0.8 165 220 48 2 4.8 2 
23 Mongajee 42 2 2778 152 55 23.81 84 150/90 - 2 30 119 0.8 210 165 51 2 3.8 2 
24 Balan 28 1 78560 170 75 25.95 96 150/90 - 1 18 108 0.5 188 147 42 2 5.4 2 
25 Giridaran 45 1 84335 173 79 26.4 95 130/90 2 1 30 107 0.8 180 132 45 2 7.6 2 
26 Fathima 45 2 2036 159 70 27.69 87 160/90 - 1 25 104 0.6 245 217 47 2 6.1 2 
27 Kannagi 45 2 2912 159 70 27.69 94 150/90 - 1 23 117 0.5 213 160 49 1 4 2 
28 Selvi 33 2 2038 158 75 30.00 86 180/90 - 2 18 90 0.5 209 160 46 2 7 2 
29 Alagan 47 1 55070 169 74 25.91 105 150/90 2 2 37 88 0.8 172 115 38 1 5.4 2 
30 Rajaram 43 1 2909 174 68 22.46 97 170/100 2 2 40 80 0.8 153 131 46 2 7.2 2 
31 Karupayya 35 1 87112 172 70 23.66 105 150/90 2 2 27 113 0.8 150 146 45 1 4.6 2 
32 Pandiyan 45 1 2884 173 67 22.39 96 160/90 2 2 40 92 1.2 193 165 42 2 5.9 2 
33 Katharnath 50 1 99 170 72 24.91 98 170/90 1 2 27 105 0.6 211 218 43 2 6 2 
34 Solaimuthu 43 1 2981 174 69 22.79 92 150/90 1 1 42 79 1 203 181 42 2 5 2 
35 Chellamuthu 28 1 2833 170 71 24.57 95 170/90 2 1 20 91 0.6 206 198 44 2 5 2 
36 Pappa 38 2 74466 156 72 29.59 95 170/100 - 1 18 82 0.6 241 181 45 1 7 2 
37 Muthumani 44 2 2488 159 70 27.69 90 160/90 - 1 20 105 0.6 160 146 42 1 6.6 2 
38 Muhamed Umar 37 1 94487 170 75 25.95 97 140/90 1 2 21 90 0.6 166 102 46 2 3.2 2 
39 Rani 46 2 994 162 67 25.53 88 180/90 - 1 22 77 0.5 296 194 45 2 4 2 
40 Usharani 40 2 2136 159 62 24.52 92 140/90 - 2 21 95 0.5 266 161 48 1 3 2 
41 Thulasimmal 38 2 4057 160 74 28.91 95 170/90 - 1 36 90 1.1 188 126 52 2 6.1 2 
42 Maniyarose 29 2 1083 162 55 20.96 82 140/90 - 2 26 91 0.7 251 148 50 2 3 2 
43 Usha 42 2 2104 155 70 29.14 89 160/90 - 1 21 98 0.5 138 145 51 2 5.8 2 
44 Susila 45 2 3502 153 62 26.49 92 170/90 - 1 24 96 0.5 194 145 52 2 6.1 2 
45 Dhanalakshmi 35 2 1438 158 72 28.84 100 150/90 - 2 22 102 0.7 187 143 47 1 5 2 
46 Chinnaponnu 49 2 81295 157 62 25.15 85 170/90 - 1 40 88 0.9 254 148 48 2 6.3 2 
47 Durairaj 40 1 113 174 74 24.44 96 140/90 1 2 37 82 0.6 168 159 38 1 4.2 2 
48 Venkatachalam 45 1 571 170 70 21.55 106 150/90 1 1 40 91 0.6 138 190 42 1 4.5 2 
49 Raji 50 2 2629 169 78 27.31 94 160/90 - 1 32 83 0.5 257 193 40 1 5 2 
50 Chellakannu 35 2 1501 157 60 24.34 86 150/90 - 2 22 105 0.5 245 193 48 1 4 2 
51 Maheswari 37 2 5785 152 61 26.4 84 150/90 - 1 29 85 0.6 146 132 52 2 4.7 2 
52 Perumal 50 1 269 174 79 26.09 100 160/90 1 1 3.7 91 0.6 248 182 45 2 5.5 2 
53 Ponnu 50 2 4725 160 64 25 95 150/90 - 2 35 81 0.7 222 190 48 1 4.5 2 
54 Sivakumar 45 1 2080 177 78 24.9 96 160/90 1 1 32 100 0.6 189 143 45 1 5.2 2 
55 Ramamoorthi 48 1 364 172 70 23.66 100 170/100 1 2 25 98 0.8 137 140 42 1 7.1 2 
56 Rabia 48 2 1419 160 71 27.73 87 150/90 - 1 35 109 0.5 190 132 52 1 4.7 2 
57 Jaled 30 1 1980 175 77 25.14 102 150/90 1 2 32 103 0.9 240 152 45 2 4.1 2 
58 Ravichandran 50 1 2800 170 80 27.68 104 170/100 2 2 39 75 0.8 183 140 42 2 7.7 2 
59 Shahiva Banu 33 2 508 152 58 25.1 86 150/90 - 2 22 82 0.7 285 193 52 2 4.9 2 
60 Malliga 30 2 193 155 62 25.81 88 150/100 - 2 37 73 0.7 270 143 50 2 5 2 
61 Ayeesha 30 2 4198 156 70 28.76 89 150/90 - 1 29 109 0.6 263 139 49 1 4.3 2 
62 Rani 25 2 2793 158 60 24.03 86 170/90  1 25 96 0.5 189 146 48 2 6.1 1 
63 Rangan 37 1 5192 174 78 25.76 100 150/90 1 1 24 98 0.7 214 167 42 2 5.5 2 
64 Muthu 26 1 2619 170 74 25.61 102 160/90 1 1 20 80 0.5 180 132 48 2 7.1 1 
65 Saravanan 33 1 4312 176 71 22.92 97 150/90 1 2 27 89 0.7 192 172 42 2 4.5 2 
66 Raju 29 1 2819 169 68 23.81 100 170/90 2 2 23 106 0.5 224 182 40 1 7.5 1 
67 Gurunathan 42 1 719 175 76 24.82 95 150/90 1 1 29 90 0.7 256 192 42 2 5.1 2 
68 Samikannan 49 1 183 165 75 27.55 105 140/90 1 1 32 82 0.5 212 148 45 2 5.6 2 
69 Samuel 32 1 2419 174 76 25.1 92 160/90 1 2 22 76 0.9 175 132 42 2 7.3 1 
70 Naganathan 40 1 19/31913 170 69 23.88 97 150/90 1 2 28 98 0.6 242 189 40 1 5.5 2 
71 Devaraj 37 1 2132 176 72 23.24 98 140/90 1 1 24 86 0.7 189 137 42 2 7.6 1 
72 Arun 25 1 2719 172 70 23.66 100 150/100 2 1 29 76 0.5 240 140 45 2 7.2 1 
73 Kumarasamy 46 1 983 174 72 23.78 105 140/90 2 2 27 105 0.9 283 176 42 1 5.6 2 
74 Beevi 42 2 5918 159 64 25.32 95 150/90 - 1 32 90 0.7 190 163 48 1 5 2 
75 Rengasamy 35 1 3319 170 68 23.53 99 160/90 2 1 26 109 0.9 240 141 45 2 6.3 2 
76 Mookan 42 1 719 176 75 24.21 100 150/90 1 1 22 90 0.5 210 145 42 1 5.5 2 
77 Sanniyasi 50 1 3519 170 78 26.99 105 140/90 1 1 32 110 0.9 239 183 38 2 7.5 1 
78 Karupasamy 40 1 919 169 72 25.21 100 150/90 2 1 35 92 0.7 240 160 42 2 6.1 2 
79 Selvi 33 2 2519 159 62 24.52 86 150/100 - 2 29 76 0.5 168 139 49 2 5.5 2 
80 Shanthi 28 2 2719 162 68 25.91 87 160/90 - 2 32 88 0.8 159 132 45 2 6.3 1 
81 Lakshmi 45 2 81875 160 65 25.39 92 150/90 - 1 36 120 0.9 240 168 47 1 4.9 2 
82 Roobi 32 2 4143 165 70 25.71 90 160/90 - 1 25 98 0.9 283 145 55 2 5.2 2 
83 Susila 39 2 7189 158 68 27.24 95 150/90 - 1 29 90 0.5 185 156 48 1 5.8 2 
84 Murugandham 40 1 5155 175 77 25.14 99 160/90 1 1 28 88 0.7 212 148 45 2 5 2 
85 Seethakumar 37 1 4193 169 72 25.21 98 150/90 1 2 26 82 0.5 214 135 42 2 4.9 2 
86 Selvam 27 1 2219 170 65 22.49 96 150/100 1 1 22 79 0.6 222 148 42 2 5 2 
87 Kuppusamy 42 1 719 160 68 26.56 100 140/90 2 2 29 98 0.9 219 135 43 2 6.1 2 
88 Elavarasan 25 1 2169 175 80 26.12 98 165/90 1 2 27 90 0.7 187 148 42 2 7.5 1 
89 Muthukumari 28 2 1793 162 62 23.62 85 150/150 - 2 22 80 0.6 219 145 41 2 5.2 2 
90 Ranganayaki 42 2 5159 159 60 23.73 84 160/90 - 2 28 76 0.5 190 137 49 2 5.5 2 
91 Prema 29 2 2719 162 61 23.24 86 160/100 - 2 25 90 0.7 210 148 51 2 6.1 1 
92 Rajamani 35 1 71925 170 72 24.91 96 150/90 - 2 30 90 0.7 210 156 42 2 5.1 2 
93 Veerapathran 48 1 8181 172 74 25.01 102 160/90 2 2 24 108 0.6 212 173 42 1 7.2 1 
94 Raja 28 1 2513 170 75 25.95 94 160/100 2 2 22 90 0.7 180 142 44 2 6.1 2 
95 Kanthasamy 40 1 7193 169 72 25.21 100 150/90 1 2 25 110 0.7 253 163 42 1 7.5 1 
96 Munjala 33 2 5192 159 72 28.48 98 150/90 - 2 29 98 0.7 168 138 51 2 5.5 2 
97 Nithya 29 2 2719 160 65 25.39 85 160/90 - 2 22 80 0.6 190 140 45 2 5.2 2 
98 Mookayee 43 2 6193 162 70 26.67 92 160/90 - 2 26 116 0.6 240 162 45 1 6.3 1 
99 Parvathi 33 2 5195 163 68 25.59 86 150/90 - 2 32 90 0.7 190 192 50 2 5.1 2 
100 Shanthi 38 2 5194 160 71 27.73 94 150/90 - 2 28 98 0.5 252 172 42 1 6.5 1 
 
Smoking : 1 – Yes ; 2 – No          Family History : 1 – Yes ; 2 – No  Metabolic Syndrome : 1 – Yes ; 2 – No  xx : 1 – elevated ; 2 - Normal 
Sex :  1 – Males  2 – Females  
 
CONTROLS 
 
S.No Name Age/Sex Op.No Ht Wt BMI Waist BP Smoking Family History Urea Sugar Creatinine Cholestrol TGL HDL 
Metabolic 
syndrome UA  
1 Sathish 36/M 95493 175 75 24.49 96 120/70 Yes Yes 24 98 0.8 164 102 52 No 3.6 No 
2 Murugadass 40/M 82843 170 69 23.88 98 120/70 No Yes 24 91 0.6 180 84 45 No 3.6 No 
3 Prabhakaran 39/M 2602 169 75 26.26 89 110/70 Yes No 24 87 0.6 219 138 50 No 3.8 No 
4 Sivam 44/M 66029 170 74 25.61 92 110/70 Yes Yes 30 94 0.8 178 150 48 No 4 No 
5 Sekar 40/M 96461 169 72 25.21 94 110/76 No No 26 87 0.7 233 153 52 No 3.5 No 
6 Moorthy 27/M 96851 175 78 25.47 98 110/82 Yes Yes 28 102 0.8 127 133 45 No 3.6 No 
7 Selvam 31/M 96883 170 72 24.91 90 110/76 No Yes 28 88 0.8 216 249 48 No 3.7 No 
8 Shanmugam 28/M 93274 169 73 25.56 88 120/70 Yes No 30 113 0.9 178 150 52 No 3.9 No 
9 Ahamed 34/M 96935 175 80 26.12 92 110/80 No Yes 28 119 0.7 236 130 45 No 3.1 No 
10 Veeran 35/M 96941 178 70 22.09 96 110/70 No No 24 91 0.8 242 144 46 No 3.4 No 
11 Ravichandran 27/M 96960 170 70 24.22 92 110/70 Yes No 26 102 0.8 202 146 50 No 3.6 No 
12 Ibrahim 37/M 96953 169 72 25.21 90 120/70 Yes Yes 28 90 0.8 198 146 52 No 3.6 No 
13 Bharathi 29/M 83317 174 70 23.12 86 110/70 No Yes 25 77 0.8 190 148 44 No 3.9 No 
14 Velasamy 30/M 97070 170 65 22.49 99 110/70 Yes No 30 98 0.9 162 149 48 No 3.5 No 
15 Raghu 39/M 97052 180 75 23.15 96 110/76 No Yes 24 100 0.7 138 145 42 No 3.9 No 
16 Saravanan 30/M 97093 174 74 24.44 92 110/70 Yes No 28 95 0.8 148 136 45 No 3.7 No 
17 Palanivel 30/M 82714 170 72 24.91 90 170/70 Yes No 20 94 0.5 200 236 42 No 4 No 
18 Sivanathan 35/M 95443 176 76 24.54 88 110/76 Yes Yes 18 105 0.6 176 94 50 No 3.5 No 
19 Chandran 50/M 98526 170 69 23.88 89 110/80 No No 18 84 0.7 180 152 48 No 6 No 
20 Murugan 35/M 98354 175 76 24.82 92 110/70 No No 20 98 0.5 188 212 45 No 4 No 
21 Kalaivanan 47/M 639 169 70 24.51 86 110/80 Yes No 25 80 0.7 202 174 46 No 4.2 No 
22 Vetrivel 45/M 971 170 70 24.22 92 110/80 No Yes 24 90 0.6 180 140 42 No 3.5 No 
23 Ramesh 28/M 19767 169 65 22.76 88 110/70 Yes No 18 76 0.7 145 108 48 No 3.2 No 
24 Suresh 29/M 761 174 70 23.12 86 110/70 Yes No 25 70 0.4 180 140 50 No 3.6 No 
25 Lakshmanan 48/M 5194 165 76 27.92 100 110/70 Yes Yes 24 110 0.9 256 176 38 Yes 4.5 No 
26 Kumar 36/M 79980 170 72 24.91 96 120/70 No Yes 24 96 0.7 180 141 42 No 3.6 No 
27 Ganesh 27/M 96941 176 69 22.28 94 110/70 Yes No 25 90 0.6 190 138 40 No 3.1 No 
28 Vignesh 43/M 96857 165 60 22.04 86 110/70 Yes No 20 70 0.4 199 170 42 No 3.7 No 
29 Ramasamy 49/M 71576 170 70 24.22 106 110/70 No Yes 25 116 0.8 283 170 40 Yes 3.8 No 
30 Thangavel 46/M 931 169 60 21.01 89 120/70 Yes Yes 26 99 0.9 190 140 42 No 3.2 No 
31 Selvi 33/F 96914 158 64 25.64 88 110/70 - No 20 90 0.6 190 142 48 No 3.2 No 
32 Chellammal 40/F 96902 160 62 24.22 86 110/70  Yes 24 86 0.7 210 138 50 No 3.8 No 
33 Rasiammal 49/F 9691 155 59 24.56 84 110/80 - Yes 36 90 0.9 180 152 52 No 3.6 No 
34 Sarima 93/F 761 150 60 26.67 86 110/70 - No 24 80 0.6 176 139 48 No 3.2 No 
35 Fathima beevi 45/F 949 154 62 26.14 90 110/80 - Yes 30 110 0.9 210 160 48 Yes 4.9 No 
36 Padmavathy 29/F 92391 156 65 26.71 82 110/70 - Yes 24 86 0.6 180 143 46 No 3.5 No 
37 Latha 26/F 92390 160 66 25.78 86 110/80 - Yes 20 90 0.6 210 156 48 No 4 No 
38 Shanthi 38/F 92486 159 62 24.52 87 110/80 - No 25 90 0.6 180 140 50 No 3.8 No 
39 Valli 39/F 92383 160 65 25.39 86 110/70 - No 24 80 0.7 213 143 48 No 3.9 No 
40 Suganthi 31/F 92385 155 60 24.97 84 110/70 - Yes 25 90 0.8 210 153 45 No 4.2 No 
41 Muthammal 46/F 92381 100 62 25.68 86 110/70 - Yes 24 70 0.6 183 140 48 No 3.8 No 
42 Jansi 42/F 92382 170 75 25.95 84 110/80 - Yes 26 90 0.7 190 143 42 No 6.1 Yes 
43 Beevi 45/F 92383 165 59 21.67 88 110/70 - No 25 110 0.7 256 183 45 Yes 6.2 Yes 
44 Rani 38/F 92384 170 65 22.49 84 110/70 - No 24 106 0.7 180 132 49 No 3.6 No 
45 Susila 42/F 92387 159 64 25.32 85 120/80 - No 29 110 0.6 190 193 55 No 3.9 No 
46 Pushpa 45/F 92390 155 58 24.14 84 110/70 - No 36 90 0.8 190 123 50 No 4.2 No 
47 Sarkasi 32/F 92391 160 59 23.05 82 110/70  No 25 70 0.6 180 110 49 No 3.6 No 
48 Pappammal 45/F 92392 165 64 23.51 86 110/76 - No 20 120 0.5 240 163 48 Yes 4.9 No 
49 Priyavathiri 29/F 92393 105 65 28.96 80 110/70 - Yes 25 96 0.6 180 132 52 No 3.2 No 
50 Rajeshwari 45/F 92994 165 60 22.04 84 110/70 - Yes 26 76 0.8 190 110 48 No 3.6 No 
51 Rajan 33/M 9531 170 74 25.61 96 110/70 No No 25 80 0.6 180 143 48 No 3.6 No 
52 Rengan 42/M 9532 180 76 23.46 90 120/80 Yes Yes 24 96 0.8 210 130 42 No 8 Yes 
53 Shanmugam 46/M 9537 165 65 23.88 88 110/80 No Yes 20 70 0.6 193 120 40 No 3.6 No 
54 Selvakumar 33/M 9534 160 59 23.05 90 110/70 No No 25 73 0.6 153 125 48 No 3.5 No 
55 Pragasam 32/M 9535 175 74 24.16 88 110/80 Yes Yes 24 86 0.7 174 137 45 No 3.6 No 
56 Balamurugan 28/M 9536 174 70 23.12 92 110/80 Yes Yes 25 90 0.6 190 140 42 No 3.7 No 
57 Ramajeyam 29/M 9537 175 70 22.86 91 110/80 Yes Yes 22 76 0.6 180 142 46 No 3.5 No 
58 Moses 36/M 9538 169 62 21.71 100 120/70 Yes Yes 26 116 0.8 253 169 37 Yes 3.6 Yes 
59 Ibrahim Ravuthar 46/M 9539 165 63 23.14 98 110/70 No Yes 24 96 0.6 190 140 40 No 4.2 No 
60 Anandhan 42/M 9540 170 65 22.49 99 110/70 No Yes 25 90 0.5 180 146 42 No 3.6 No 
61 Annasi 46/M 9541 172 68 22.99 86 110/80 Yes No 24 86 0.4 176 136 40 No 3.2 No 
62 Andiyappan 48/M 9542 170 65 22.49 88 110/70 No No 28 90 0.6 210 150 42 No 7.2 Yes 
63 Karthick 27/M 9543 172 63 21.3 84 110/76 Yes Yes 32 86 0.5 190 102 48 No 3.5 No 
64 Moorthy 28/M 9544 165 70 25.71 82 110/70 Yes No 30 92 0.6 186 110 46 No 3.2 No 
65 Krishnan 42/M 9546 169 72 25.21 90 120/80 Yes Yes 28 102 0.7 210 138 42 No 3.9 No 
66 Sethuraman 46/M 9547 168 79 27.99 92 120/80 No No 29 8 0.6 253 190 37 No 7.2 Yes 
67 Karmegam 38/F 9548 165 72 26.45 88 110/80 No No 25 90 0.5 190 143 42 No 3.3 No 
68 Muthu 29/M 9549 170 70 24.22 86 110/80 No No 24 80 0.6 117 142 45 No 3.7 No 
69 Thangavel 33/M 9550 175 66 21.55 90 120/80 Yes Yes 24 99 0.5 180 138 46 No 3.8 No 
70 Palanisamy 36/M 9551 175 60 20.59 90 120/80 No Yes 22 96 0.7 190 112 40 No 3.7 No 
71 Mookammal 46/F 9552 159 60 23.73 86 110/70 - Yes 24 90 0.6 190 140 48 No 3.2 No 
72 Chitradevi 37/F 9553 160 62 24.22 84 120/80 - No 25 91 0.8 210 133 45 No 3.6 No 
73 Radha 25/F 9554 162 58 22.1 82 110/70 - No 26 70 0.7 183 143 50 No 4.1 No 
74 Neelaveni 46/F 9555 165 65 23.88 85 120/80 - Yes 32 76 0.8 195 102 52 No 5 No 
75 Thangam 46/F 9556 155 60 24.97 87 120/70 - Yes 36 87 0.9 180 176 48 No 3.6 No 
76 Rajeswari 37/F 9557 162 69 26.29 84 110/70 - No 24 90 0.5 153 110 55 No 3.1 No 
77 Nagammal 48/F 9558 161 65 25.08 100 120/80 - No 30 112 0.5 290 173 48 Yes 4.9 No 
78 Rosi 22/F 9555 165 67 24.61 86 110/70 - Yes 20 90 0.6 180 102 56 No 4.1 No 
79 Nallammal 45/M 9560 159 59 23.34 86 120/80 - Yes 22 92 0.9 210 163 55 No 3.8 No 
80 Bhavani 43/F 5561 160 60 23.44 80 110/70 - No 23 70 0.6 220 183 52 No 4.7 No 
81 Lakhsmi 46/F 9562 159 62 24.52 84 110/70 - No 26 86 0.6 180 140 54 No 4.1 No 
82 Malarvili 23/F 9563 160 62 24.22 80 110/70 - Yes 28 82 0.7 193 139 48 No 4.2 No 
83 Jeyamani 38/F 9564 170 76 26.3 82 120/80 - No 28 84 0.5 199 127 53 No 3.6 No 
84 Backiyam 39/F 9565 159 72 28.48 89 110/70 - Yes 26 116 0.7 253 183 45 Yes 4 No 
85 Thangammal 49/F 9566 160 62 24.22 85 110/70 - Yes 26 90 0.6 200 102 54 No 3.6 No 
86 Rosathi 35/F 9567 160 59 23.05 84 120/80 - Yes 28 92 0.6 149 167 55 No 3.7 No 
87 Maheswari 29/F 9568 160 70 27.34 80 110/70 - No 26 96 0.5 167 102 56 No 3.2 No 
88 Velliammal 42/F 9569 155 62 25.81 90 120/80 - Yes 27 98 0.5 189 108 52 No 3.6 No 
89 Palaniammal 46/F 9570 157 63 25.56 85 110/70 - No 20 100 0.4 210 125 50 No 3.8 No 
90 Shenbagam 39/F 9572 160 60 23.44 83 110/70 - Yes 25 90 0.5 210 145 52 No 5.1 No 
91 Shanthi 23/F 9573 158 60 24.03 81 120/80 - Yes 25 89 0.5 220 159 48 No 3.9 No 
92 Eswari 28/F 9574 161 65 25.08 85 110/70 - Yes 30 86 0.6 183 140 48 No 3.2 No 
93 Raman 34/F 9575 170 66 22.84 90 120/70 No Yes 26 76 0.5 210 163 42 No 4.1 No 
94 Kumar 43/M 9576 170 67 23.18 94 110/70 Yes No 27 85 0.4 147 168 40 No 4.1 No 
95 Ramanathan 46/M 9577 165 80 29.38 92 110/70 Yes Yes 29 182 0.8 280 175 34 Yes 4.9 No 
96 Sankar 23/M 9578 175 76 24.82 93 110/80 Yes Yes 30 36 0.8 212 143 46 No 3.8 No 
97 Maharajan 29/M 9579 173 66 22.05 95 110/80 Yes No 32 101 0.9 219 144 47 No 3.9 No 
98 Mujahiv 42/M 9580 175 68 22.2 90 110/70 Yes Yes 25 96 0.6 146 193 42 No 3.1 No 
99 Sankar 23/M 9578 175 76 24.82 93 110/80 Yes Yes 30 36 0.8 212 143 46 No 3.8 No 
100 Velayu 39/M 9581 170 70 24.22 90 110/70 Yes Yes 24 94 0.7 150 109 49 No 3.1 No 
 
